“CRISPR Therapies Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the CRISPR Therapies Market.
The CRISPR Therapies Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
CRISPR Therapies Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into emerging therapies in the CRISPR Market and the aggregate therapies developed by major pharma companies.
-
It accesses the different CRISPR therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development.
-
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the CRISPR Therapies Market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, featured press releases from company/university websites, industry-specific third-party sources, etc.
Learn How the Ongoing Clinical & Commercial Activities will Affect the CRISPR Therapies Therapeutic Segment @
https://www.delveinsight.com/sample-request/crispr-therapies-pipeline-insight
Phases of Emerging Therapies
DelveInsight’s Report covers around 30+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Route of Administration
CRISPR Therapies pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Oral
-
Parenteral
-
Intravenous
-
Subcutaneous
-
Topical
Molecule Type
Products have been categorized under various Molecule types such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
CRISPR Therapies Therapeutics Landscape
There are approx. 25+ key companies which are developing CRISPR Therapies. Currently, CRISPR Therapeutics is leading the therapeutics market with its CRISPR Therapies drug candidates in the most advanced stage of clinical development.
Leading CRISPR Therapies Companies in the Therapeutics Market Include:
-
Intellia Therapeutics
-
CRISPR therapeutics
-
Repare Therapeutics
-
Beam therapeutics
-
Caribou Biosciences
-
Emendo Biotherapeutics
-
Defence Therapeutics
-
Sarepta therapeutics
-
Editas Medicine
-
Locus Biosciences
-
Excision BioTherapeutics
-
AstraZeneca
-
Novartis
-
ASC therapeutics
-
Casebia therapeutics
-
Spotlight Therapeutics
-
KSQ Therapeutics
-
MEDIC Life Sciences
-
Scribe therapeutics
-
Arbor Biotechnologies
-
Sangamo therapeutics
-
Graphite Bio
-
Nuntius Therapeutics
And Many Others
CRISPR Therapies Emerging and Marketed Drugs Covered in the Report Include:
-
CTX001: CRISPR Therapeutics
-
EDIT-101: Editas Medicine
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @
https://www.delveinsight.com/sample-request/crispr-therapies-pipeline-insight
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. CRISPR Therapies Current Treatment Patterns
4. CRISPR Therapies - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. CRISPR Therapies Late Stage Products (Phase-III)
7. CRISPR Therapies Mid-Stage Products (Phase-II)
8. CRISPR Therapies Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. CRISPR Therapies Discontinued Products
13. CRISPR Therapies Product Profiles
14. CRISPR Therapies Companies in the Market
15. Key Products in the CRISPR Therapies Therapeutics Segment
16. Dormant and Discontinued Products
17. CRISPR Therapies Unmet Needs
18. CRISPR Therapies Future Perspectives
19. CRISPR Therapies Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/crispr-therapies-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
"Traveler's Diarrhea Market Insights, Epidemiology, and Market Forecast-2032" report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Traveler's Diarrhea market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Traveler's Diarrhea market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
